Nivolumab + CCR2/CCR5 dual antagonist + GVAX

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma

Trial Timeline

Dec 12, 2019 → Feb 1, 2025

NCT ID

NCT03767582

About Nivolumab + CCR2/CCR5 dual antagonist + GVAX

Nivolumab + CCR2/CCR5 dual antagonist + GVAX is a phase 1/2 stage product being developed by Bristol Myers Squibb for Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC). The current trial status is completed. This product is registered under clinical trial identifier NCT03767582. Target conditions include Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03767582	Phase 1/2	Completed	Dec 12, 2019	Feb 1, 2025	Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Competing Products

20 competing products in Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
NBTXR3	Nanobiotix	Phase 1/2	36
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
zolbetuximab	Astellas Pharma	Pre-clinical	23
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	77
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	23
zolbetuximab	Astellas Pharma	Pre-clinical	23
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	77
ASP3082	Astellas Pharma	Phase 2	52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	77
ASP1948	Astellas Pharma	Phase 1	33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved